Monoclonal antibody against VP0 recognizes a broad range of human parechoviruses.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
07 2021
Historique:
received: 29 11 2020
revised: 17 03 2021
accepted: 15 04 2021
pubmed: 25 4 2021
medline: 25 11 2021
entrez: 24 4 2021
Statut: ppublish

Résumé

Parechoviruses (PeVs) are common viruses that cause mild gastrointestinal or respiratory symptoms to severe central nervous system infections. In infants, parechovirus infection is one of the leading causes of life-threatening viral disease. High-quality antibodies with broad binding specificities are essential to improve accurate parechovirus diagnosis in diagnostic laboratories. Such antibodies have potential in the development of rapid antigen detection assay against PeVs. In the present study, VP4 and VP2 genes from human parechovirus A1 (PeV-A1) were cloned and VP0 fusion protein produced to develop monoclonal antibodies against PeVs. Two pan-parechovirus antibodies, one IgG and one IgM isotype, were isolated. The properties of IgG1/κ monoclonal (designated as Mab-PAR-1) was studied further. Mab-PAR-1 was shown to be functional in western blot against denatured recombinant protein and viral particles. In immunofluorescence assay, the antibody tested positive for nineteen PeV-A1 isolates while showing no cross-reactivity to fourteen entero- and rhinovirus types. In addition, Mab-PAR-1 showed positive reactivity against five other cultivable parechovirus types 2-6. A unique Mab-PAR-1 epitope located in the junction of the three capsid proteins VP0, VP1, and VP3 was identified using a peptide library screen. This study demonstrates that PeV-A1-VP0 protein is functional antigen for developing monoclonal antibody for diagnosis of broad range of parechovirus infections.

Identifiants

pubmed: 33894205
pii: S0166-0934(21)00106-3
doi: 10.1016/j.jviromet.2021.114167
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Capsid Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114167

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Lav Tripathi (L)

Institute of Biomedicine, University of Turku, Turku, Finland. Electronic address: lav.tripathi@utu.fi.

Eero Hietanen (E)

Institute of Biomedicine, University of Turku, Turku, Finland.

Pirjo Merilahti (P)

Institute of Biomedicine, University of Turku, Turku, Finland.

Laura Teixido (L)

Clinisciences Ltd, Bellaterra, Spain.

Neus Sanchez-Alberola (N)

Clinisciences Ltd, Bellaterra, Spain.

Sisko Tauriainen (S)

Institute of Biomedicine, University of Turku, Turku, Finland.

Petri Susi (P)

Institute of Biomedicine, University of Turku, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH